UCB reports new clinical data on generalized myasthenia gravis portfolio at AAN 2026

UCB says it will present new clinical data from its generalized myasthenia gravis portfolio at the 2026 American Academy of Neurology meeting.

In an April 13 announcement, the company said two studies examined zilucoplan auto-injector administration compared with pre-filled syringe use in adults with gMG and healthy volunteers. UCB said it is presenting 21 abstracts in total from its neurology portfolio at AAN 2026, including six myasthenia gravis abstracts.

The company’s later official release on its zilucoplan pre-filled pen says the same data will be presented at the meeting in Chicago from April 18 to 22, 2026. The AAN 2026 abstract website is also live and includes related gMG abstracts.

UCB did not disclose all topline results in the release, but the announcement adds to the company’s ongoing push in myasthenia gravis treatment and delivery options.

The conference presentation will provide more detail on the findings once the meeting opens.